Henry Schein (NASDAQ:HSIC) CEO Sells $3,562,353.72 in Stock

Henry Schein, Inc. (NASDAQ:HSIC) CEO Stanley Bergman sold 43,812 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $81.31, for a total transaction of $3,562,353.72. Following the completion of the transaction, the chief executive officer directly owned 383,803 shares in the company, valued at $31,207,021.93. This represents a 10.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Henry Schein Price Performance

Henry Schein stock opened at $80.17 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.76. The stock has a market cap of $9.20 billion, a price-to-earnings ratio of 24.52, a price-to-earnings-growth ratio of 2.38 and a beta of 0.88. The firm has a 50-day moving average of $78.17 and a two-hundred day moving average of $72.50. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $89.29.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.04. The firm had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company’s revenue was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, research analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. CYBER HORNET ETFs LLC bought a new position in shares of Henry Schein during the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc acquired a new position in shares of Henry Schein during the second quarter worth $27,000. Flagship Harbor Advisors LLC acquired a new position in shares of Henry Schein during the fourth quarter worth $30,000. Federated Hermes Inc. purchased a new stake in shares of Henry Schein during the 4th quarter valued at $32,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Henry Schein in the 4th quarter worth $37,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Analysts Set New Price Targets

HSIC has been the topic of a number of recent research reports. Wall Street Zen raised Henry Schein from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. Weiss Ratings reiterated a “hold (c)” rating on shares of Henry Schein in a report on Monday, December 29th. Wells Fargo & Company raised their target price on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. Barrington Research set a $97.00 price target on shares of Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Finally, Morgan Stanley increased their price objective on shares of Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a research note on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $85.58.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.